NCT03609112Recruiting
Neurocognitive Risks in Children With Solid Tumors
Source: ClinicalTrials.gov · Last updated 13 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The survival rate of children with cancer has improved significantly in recent years thanks to the progress of different therapies. The neurocognitive sequelae related to treatments and illness are more or less well known. Four factors seem to be associated with neurocognitive sequelae: treatment, the tumor itself, environmental factors like the socio-economic status of parents and biological factors. Main purpose of the study is to establish a score to assess the risk of neurocognitive sequelae in these children based on these factors (treatment, tumor, and environmental factors)
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 24 Jul 2018
- Start date
- 1 Oct 2014
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Diseases
- Childhood cancers
- NCT number
- NCT03609112
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Oct 2014 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other pathologies associated with mental retardation (autism, genetic syndrome ...)
Other
- Patients lost to follow-up
- Deceased patients
- Patients treated for a pathology whose prognosis is involved in the very short term (infiltrating glioma of the brainstem, recurrence of the pathology during treatment)
- Non-French speaking patients
Who the study is looking for
- Patient aged 6 to 16 years and 11 months during the study period
- Type of pathology: solid tumor
- Place of treatment and follow-up: Gustave Roussy
- Minimum time from the end of the initial treatment:
- For patients who have not received treatment with methotrexate: 6 months
- For patients being treated with methotrexate: none
- Obtaining the non-opposition of parents / legal representatives
- Affiliation to a social security scheme.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.